Triptorelin is a peptide formulation for injection that was developed mainly for the treatment of advanced metastatic prostate cancer. Furthermore, other indications developed subsequently include the treatment of uterine fibroids (a benign tumor of muscle tissues in the uterus), endometriosis (proliferation of endometrial tissue, the mucous membrane that lines the uterine wall outside the reproductive tract) prior to surgery or when surgery is not deemed appropriate, as well as early onset puberty and female infertility (in vitro fertilization). Other modalities of triptorelin such as triptorelin acetate, triptorelin pamoate and triptorelin embonate are also used for prostate cancer treatment.

Market Dynamics

Triptorelin market is expected to witness lucrative growth opportunities during forecast period, owing to increasing incidence of prostate cancer and salivary gland cancer and increasing prevalence of central precocious puberty among the young patients below age eight and nine years, worldwide. For instance, according to National Organization for Rare Disorders (NORD), 2016 data findings, Central Precocious Puberty (CPP), accounted for 1 to 5 in 10,000 children with a female to male ratio of about 20:1, in U.S.

In March 2017, Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK, in coordination with fourteen other European regulatory agencies approved a new indication of Decapeptyl (triptorelin). According to these new indication, Decapeptyl (triptorelin) will be used as adjuvant treatment in combination with tamoxifen or aromatase inhibitor for endocrine-responsive early-stage breast cancer in women at high-risk of recurrence who are confirmed as pre-menopausal after completion of chemotherapy. This would enhance the revenue for growth for triptorelin market, during forecast period.

Furthermore, higher efficacy and tolerability of triptorelin in suppression of gonadotropin secretion in prostate cancer and precocious puberty is increasing adoption of triptorelin in the market.

Key features of the study

• This report provides in-depth analysis of triptorelin market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017, as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
• It profiles leading players in the global triptorelin market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
• Key companies covered as a part of this study include Ipsen, Bachem, Ferring Pharmaceuticals Pvt Ltd., Chengdu Tiantaishan pharmaceutical Co., Ltd., Tecnofarma, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd. (Actavis Specialty Pharmaceuticals Co.), Debiopharm Group, and Arbor Pharmaceuticals, LLC.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
• The global triptorelin market report caters to various stakeholders in this industry including investors, suppliers, triptorelin based product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the triptorelin market.

Market Segmentation

• By Drug Type (Revenue, USD Mn, 2021-2033)
  • Triptorelin pamoate
  • Triptorelin acetate
  • Triptorelin embonate.
• By Application (Revenue, USD Mn, 2021-2033)
  • Prostate Cancer
  • Radical Prostatectomy
  • Endometriosis
  • Salivary Gland Cancer
  • Central Precocious Puberty
• By Distribution Channel (Revenue, USD Mn, 2021-2033)
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
• By Region (Revenue, USD Mn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa
• Key Players
  • Ipsen
  • Bachem
  • Ferring Pharmaceuticals Pvt Ltd.
  • Chengdu Tiantaishan pharmaceutical Co., Ltd.,
  • Tecnofarma
  • Reddy’s Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd. (Actavis Specialty Pharmaceuticals Co.)
  • Debiopharm Group
  • Arbor Pharmaceuticals, LLC.